Detalhe da pesquisa
1.
A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma.
Int J Cancer
; 153(5): 1026-1034, 2023 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37246577
2.
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma.
Pediatr Blood Cancer
; 63(1): 39-46, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26235333
3.
Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.
Genome Med
; 16(1): 28, 2024 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38347552
4.
A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.
Cancer Rep (Hoboken)
; 5(11): e1616, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35355452
5.
Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma.
Cancer Med
; 4(6): 871-86, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25720842
6.
Poor predictability of prenatal ultrasonography for a nonfunctional kidney.
Urology
; 60(4): 697, 2002 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-12385943